Avenue Therapeutics Inc Financials

ATXI

Source SEC Filings (10-K/10-Q) Updated Dec 31, 2025 Currency USD FYE December

This page shows Avenue Therapeutics Inc (ATXI) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 11 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI ATXI FY2025 2026-04-22

Avenue Therapeutics remains a cash-funded development company, with administrative overhead now carrying more weight than active research spending.

FY2025's most important shift was research retrenchment: R&D fell from $6.6M to $1.0M, which made the business look less cash-hungry not because it became profitable, but because spending was cut back sharply. Because SG&A still exceeded R&D and operating cash outflow was $1.8M against a net loss of $2.9M, the remaining cost base looks more like corporate overhead than an expanding development effort.

The balance sheet is still cash-heavy in a narrow sense—cash of $2.9M exceeded total liabilities of $1.1M—but that cushion has been rebuilt with financing inflows rather than operating inflows. The rise in shares outstanding from 2.1M to 3.2M reinforces that liquidity has depended on outside funding, so the cash balance says more about fundraising than business self-sufficiency.

The new revenue line of $1.4M did not change the economic shape of the business, because the operating margin was still -219.6%. That means FY2025 looked less like a self-supporting operating business and more like smaller burn after a sharp reduction in development spending.

Financial Health Signals

Financial Profile 32/100

Based on FY2025 annual data, averaged across the last 3 years for performance metrics (most-recent year weighted highest). How this score is calculated →

Health score ≠ stock price. This rates the quality of Avenue Therapeutics Inc's business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.

Profitability

Avenue Therapeutics Inc has an operating margin of -219.6%, meaning the company retains $-220 of operating profit per $100 of revenue. This below-average margin results in a low score of 0/100, suggesting thin profitability after operating expenses.

Leverage

Avenue Therapeutics Inc carries a low D/E ratio of 0.60, meaning only $0.60 of long-term debt for every $1 of shareholders' equity. This conservative leverage earns a score of 90/100, indicating a strong balance sheet with room for future borrowing.

Returns

Avenue Therapeutics Inc generates a -158.8% ROE, indicating limited profit relative to shareholders' investment. This results in a returns score of 0/100. This is up from -416.6% the prior year.

Piotroski F-Score Weak

3/9

Avenue Therapeutics Inc passes 3 of 9 financial strength tests. 2 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution), both operating efficiency signals pass.

Earnings Quality Low Quality

0.63x

For every $1 of reported earnings, Avenue Therapeutics Inc generates $0.63 in operating cash flow (-$1.8M OCF vs -$2.9M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue

$1.4M

Avenue Therapeutics Inc generated $1.4M in revenue in fiscal year 2025.

EBITDA

N/A

Net Income

-$2.9M

YoY+75.0%

Avenue Therapeutics Inc reported -$2.9M in net income in fiscal year 2025. This represents an increase of 75.0% from the prior year.

EPS (Diluted)

N/A

Cash & Balance Sheet

Free Cash Flow

N/A

Cash & Debt

$2.9M

YoY+10.1%

5Y CAGR-1.8%

10Y CAGR+70.2%

Avenue Therapeutics Inc held $2.9M in cash against $0 in long-term debt as of fiscal year 2025.

Dividends Per Share

N/A

Shares Outstanding

YoY+51.0%

Avenue Therapeutics Inc had 3M shares outstanding in fiscal year 2025. This represents an increase of 51.0% from the prior year.

Margins & Returns

Gross Margin

N/A

Operating Margin

-219.6%

Avenue Therapeutics Inc's operating margin was -219.6% in fiscal year 2025, reflecting core business profitability.

Net Margin

-207.2%

Avenue Therapeutics Inc's net profit margin was -207.2% in fiscal year 2025, showing the share of revenue converted to profit.

Return on Equity

-158.8%

YoY+257.8pp

5Y CAGR+59.6pp

Avenue Therapeutics Inc's ROE was -158.8% in fiscal year 2025, measuring profit generated per dollar of shareholder equity. This is up 257.8 percentage points from the prior year.

Capital Allocation

R&D Spending

$1.0M

YoY-84.4%

5Y CAGR-18.4%

10Y CAGR+0.8%

Avenue Therapeutics Inc invested $1.0M in research and development in fiscal year 2025. This represents a decrease of 84.4% from the prior year.

Share Buybacks

N/A

Capital Expenditures

N/A

ATXI Income Statement

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Revenue	$1.4M	$0	N/A	N/A	N/A	N/A
Cost of Revenue	N/A	N/A	N/A	N/A	N/A	N/A
Gross Profit	N/A	N/A	N/A	N/A	N/A	N/A
R&D Expenses	$1.0M-84.4%	$6.6M+8.4%	$6.1M+127.2%	$2.7M+115.2%	$1.3M-56.2%	$2.9M
SG&A Expenses	$3.7M-21.2%	$4.6M+11.0%	$4.2M-21.8%	$5.3M+115.2%	$2.5M+5.8%	$2.3M
Operating Income	-$3.1M+72.7%	-$11.3M	N/A	-$8.0M-115.2%	-$3.7M+28.3%	-$5.2M
Interest Expense	N/A	N/A	N/A	N/A	N/A	N/A
Income Tax	$2K	$0	$0	$0	N/A	N/A
Net Income	-$2.9M+75.0%	-$11.7M	N/A	-$3.6M+4.8%	-$3.7M+27.6%	-$5.2M
EPS (Diluted)	N/A	N/A	N/A	N/A	$-0.22	$-0.31

Metric	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24	Q1'24
Revenue	N/A	$0-100.0%	$1.4M	N/A	N/A	$0	$0	N/A
Cost of Revenue	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Gross Profit	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
R&D Expenses	N/A	$177K-7.8%	$192K-53.3%	$411K	N/A	$2.3M+71.0%	$1.4M-43.1%	$2.4M
SG&A Expenses	N/A	$547K-40.2%	$915K-38.8%	$1.5M	N/A	$829K-43.3%	$1.5M+11.1%	$1.3M
Operating Income	N/A	-$724K-343.8%	$297K+115.6%	-$1.9M	N/A	-$3.2M-11.8%	-$2.8M+23.9%	-$3.7M
Interest Expense	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Income Tax	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Net Income	N/A	-$683K-303.9%	$335K+118.1%	-$1.9M	N/A	-$3.1M-14.3%	-$2.7M+38.0%	-$4.3M
EPS (Diluted)	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

ATXI Balance Sheet

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Total Assets	$2.9M+9.7%	$2.7M+44.4%	$1.9M-73.0%	$6.8M+72.9%	$4.0M+22.0%	$3.2M
Current Assets	N/A	N/A	N/A	N/A	$4.0M+22.0%	$3.2M
Cash & Equivalents	$2.9M+10.1%	$2.6M+45.5%	$1.8M-73.4%	$6.7M+78.3%	$3.8M+20.1%	$3.1M
Inventory	N/A	N/A	N/A	N/A	N/A	N/A
Accounts Receivable	N/A	N/A	N/A	N/A	N/A	N/A
Goodwill	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$1.1M+979.2%	-$125K-146.6%	$268K-92.5%	$3.6M+603.1%	$509K-42.6%	$886K
Current Liabilities	$1.1M+34.7%	$816K	N/A	$3.6M+603.1%	$509K-42.6%	$886K
Long-Term Debt	N/A	N/A	N/A	N/A	N/A	N/A
Total Equity	$1.8M-34.5%	$2.8M+76.8%	$1.6M-59.5%	$3.9M+13.2%	$3.5M+46.3%	$2.4M
Retained Earnings	-$105.5M-2.8%	-$102.6M-12.8%	-$90.9M-12.9%	-$80.6M-4.6%	-$77.0M-5.1%	-$73.3M

Metric	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24	Q1'24
Total Assets	$2.9M-21.3%	$3.7M-10.5%	$4.2M+15.8%	$3.6M+34.5%	$2.7M+1.8%	$2.6M-47.4%	$5.0M+50.7%	$3.3M
Current Assets	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Cash & Equivalents	$2.9M-23.0%	$3.7M+11.5%	$3.3M-5.0%	$3.5M+35.0%	$2.6M-0.1%	$2.6M-47.2%	$4.9M+54.0%	$3.2M
Inventory	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Accounts Receivable	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Goodwill	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$1.1M+554.2%	$168K+63.1%	$103K+22.6%	$84K+167.2%	-$125K-933.3%	$15K-98.7%	$1.2M+144.9%	$474K
Current Liabilities	$1.1M	N/A	N/A	N/A	$816K	N/A	$1.2M	N/A
Long-Term Debt	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Equity	$1.8M-48.5%	$3.6M-12.3%	$4.1M+15.6%	$3.5M+25.5%	$2.8M+7.2%	$2.6M-45.2%	$4.8M+68.0%	$2.8M
Retained Earnings	-$105.5M-0.7%	-$104.8M-0.7%	-$104.1M+0.3%	-$104.4M-1.8%	-$102.6M-1.5%	-$101.0M-3.1%	-$98.0M-2.8%	-$95.3M

ATXI Cash Flow Statement

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Operating Cash Flow	-$1.8M+79.7%	-$9.0M	N/A	-$7.6M-102.6%	-$3.8M+18.7%	-$4.6M
Capital Expenditures	N/A	N/A	N/A	N/A	N/A	N/A
Free Cash Flow	N/A	N/A	N/A	N/A	N/A	N/A
Investing Cash Flow	N/A	$0+100.0%	-$3.0M	$0	N/A	-$1.0M
Financing Cash Flow	$2.1M-78.7%	$9.8M+30.7%	$7.5M-28.6%	$10.5M+140.6%	$4.4M	$0
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	$0-100.0%	$1.1M	N/A	N/A

Metric	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24	Q1'24
Operating Cash Flow	-$854K-323.0%	$383K+317.6%	-$176K+85.2%	-$1.2M-55.2%	-$764K+73.6%	-$2.9M-28.2%	-$2.3M+27.8%	-$3.1M
Capital Expenditures	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Free Cash Flow	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Investing Cash Flow	N/A	N/A	N/A	N/A	$0	$0	N/A	N/A
Financing Cash Flow	$0	$0	$0-100.0%	$2.1M+175.2%	$761K+34.2%	$567K-85.7%	$4.0M-12.2%	$4.5M
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

ATXI Financial Ratios

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Gross Margin	N/A	N/A	N/A	N/A	N/A	N/A
Operating Margin	-219.6%	N/A	N/A	N/A	N/A	N/A
Net Margin	-207.2%	N/A	N/A	N/A	N/A	N/A
Return on Equity	-158.8%+257.8pp	-416.6%	N/A	-91.0%+17.1pp	-108.1%+110.3pp	-218.4%
Return on Assets	-99.3%+336.8pp	-436.1%	N/A	-51.9%+42.3pp	-94.2%+64.5pp	-158.7%
Current Ratio	N/A	N/A	N/A	N/A	7.78+4.1	3.66
Debt-to-Equity	0.60+0.6	-0.04-0.2	0.17-0.7	0.92+0.8	0.15-0.2	0.38
FCF Margin	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24	Q1'24
Gross Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Operating Margin	N/A	N/A	21.1%	N/A	N/A	N/A	N/A	N/A
Net Margin	N/A	N/A	23.9%	N/A	N/A	N/A	N/A	N/A
Return on Equity	N/A	-19.2%-27.5pp	8.3%+61.0pp	-52.8%	N/A	-117.9%-61.3pp	-56.5%+96.5pp	-153.0%
Return on Assets	N/A	-18.3%-26.4pp	8.1%+59.6pp	-51.5%	N/A	-117.2%-63.2pp	-54.0%+77.1pp	-131.1%
Current Ratio	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Debt-to-Equity	0.60+0.6	0.05+0.0	0.030.0	0.02+0.1	-0.04-0.1	0.01-0.2	0.24+0.1	0.17
FCF Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Similar Companies

Restart Life NMLSF

$2.9M

Mosaic Immunoengineering Inc CPMV

$2.4M

Mynd Life Scienc MYNDF

$895K

Nascent Biotech NBIO

$3.3M

Algernon Health AGNPF

$217K

Frequently Asked Questions

What is Avenue Therapeutics Inc's annual revenue?

Avenue Therapeutics Inc (ATXI) reported $1.4M in total revenue for fiscal year 2025. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

Is Avenue Therapeutics Inc profitable?

No, Avenue Therapeutics Inc (ATXI) reported a net income of -$2.9M in fiscal year 2025, with a net profit margin of -207.2%.

What is Avenue Therapeutics Inc's operating margin?

Avenue Therapeutics Inc (ATXI) had an operating margin of -219.6% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.

What is Avenue Therapeutics Inc's net profit margin?

Avenue Therapeutics Inc (ATXI) had a net profit margin of -207.2% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.

What is Avenue Therapeutics Inc's return on equity (ROE)?

Avenue Therapeutics Inc (ATXI) has a return on equity of -158.8% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.

What is Avenue Therapeutics Inc's operating cash flow?

Avenue Therapeutics Inc (ATXI) generated -$1.8M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.

What are Avenue Therapeutics Inc's total assets?

Avenue Therapeutics Inc (ATXI) had $2.9M in total assets as of fiscal year 2025, including both current and long-term assets.

How much does Avenue Therapeutics Inc spend on research and development?

Avenue Therapeutics Inc (ATXI) invested $1.0M in research and development during fiscal year 2025.

How many shares does Avenue Therapeutics Inc have outstanding?

Avenue Therapeutics Inc (ATXI) had 3M shares outstanding as of fiscal year 2025.

What is Avenue Therapeutics Inc's debt-to-equity ratio?

Avenue Therapeutics Inc (ATXI) had a debt-to-equity ratio of 0.60 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is Avenue Therapeutics Inc's return on assets (ROA)?

Avenue Therapeutics Inc (ATXI) had a return on assets of -99.3% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

What is Avenue Therapeutics Inc's cash runway?

Based on fiscal year 2025 data, Avenue Therapeutics Inc (ATXI) had $2.9M in cash against an annual operating cash burn of $1.8M. This gives an estimated cash runway of approximately 19 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.

What is Avenue Therapeutics Inc's Piotroski F-Score?

Avenue Therapeutics Inc (ATXI) has a Piotroski F-Score of 3 out of 9, indicating weak financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are Avenue Therapeutics Inc's earnings high quality?

Avenue Therapeutics Inc (ATXI) has an earnings quality ratio of 0.63x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

How financially healthy is Avenue Therapeutics Inc?

Avenue Therapeutics Inc (ATXI) scores 32 out of 100 on our Financial Profile, indicating weak overall financial health. This composite score evaluates six dimensions: profitability (operating margin), revenue growth, leverage (debt-to-equity), liquidity (current ratio), cash flow quality (free cash flow margin), and shareholder returns (return on equity). Each dimension is normalized against standard financial benchmarks. Learn more in our complete guide to financial health indicators.